CTIS2023-503686-26-00Active, not recruitingPhase 1
PET/CT imaging with FAPI as a biomarker for the distinction between predominant active fibrotic and inflammatory phenotypes in patients with progressive pulmonary fibrosis: The FIBRO-PET study.
Conditions
Trial Snapshot
- Phase
- Phase 1
- Status
- Active, not recruiting
- Sponsor
- St Antonius Hospital
- Enrollment
- 20
Study Overview
Brief Summary
No summary available.
Study Design
- Study Type
- Interventional
Eligibility Criteria
- Ages
- 18 to 65+ (—)
- Sex
- All
Inclusion Criteria
- •= 18 years of age, New diagnosis of PPF, A minimum of 20% of lung parenchyma is aberrant (fibrosis, inflammation or both), MDT indication for treatment with either immunosuppressive drugs or antifibrotic drug
Exclusion Criteria
- •Prior or current treatment with antifibrotic drugs, Active malignancy, Inability to undergo a PET/CT at the Sint Antonius Hospital, Incapacity to give informed consent personally, Pregnancy
Investigators
Similar Trials
Not yet recruiting
Not Applicable
The diagnostic value of FAPI PET/CT in staging of newly diagnosed PCa10038597Prostate cancerNL-OMON53628Antoni van Leeuwenhoek Ziekenhuis30
Recruiting
Unknown
Pathophysiological assessment by FAPI-PET targeting cancer-associated fibroblasts in proton therapyCancerJPRN-UMIN000052534Southern Tohoku Research Institute for Neuroscience80
Unknown
Not Applicable
Visualized Monitoring of Fibrosis Formation in Heart Failure With 68GA-FAPI PETPositron Emission TomographyHeart FailureNCT04982458Wuhan Union Hospital, China50
Active, not recruiting
Phase 1
The use of FES-PET imaging as a tool to detect a possible reversion of Estrogen Receptor (ER)-a status in patients with metastatic breast cancer HER2 + and ERa neg treated with trastuzumab + pertuzumab + taxane.Metastatic breast cancer HER2 + and ERa neg.MedDRA version: 20.0Level: LLTClassification code 10027475Term: Metastatic breast cancerSystem Organ Class: 100000004864EUCTR2018-001552-36-FRINSTITUT CLAUDIUS REGAUD33
Active, not recruiting
Phase 1
A bone scan in combination with some specific blood samples for the classification of bone disease in patients suffering from chronic kidney disease.Chronic Kidney Disease - Mineral and Bone Disorder (CKD-MBD), especially renal osteodystofi.MedDRA version: 20.0 Level: LLT Classification code 10065404 Term: Combined positron emission tomogram and computerised tomogram System Organ Class: 10022891 - InvestigationsMedDRA version: 20.0 Level: SOC Classification code 10022891 Term: Investigations System Organ Class: 10022891 - InvestigationsMedDRA version: 20.0 Level: LLT Classification code 10066622 Term: Chronic hemodialysis System Organ Class: 100000004865EUCTR2016-005160-34-DKniversitetsklinikken for Nyresygdomme og Blodtryksforhøjelse, Regionshospitalet Holstebro, Hospitalsenheden Vest40